Research Study on Whether a Combination of 2 Medicines Works in People With Non-alcoholic Steatohepatitis (NASH)

Research Study on Whether a Combination of 2 Medicines Works in People With Non-alcoholic Steatohepatitis (NASH)
Recruiting
18 years - 99 years
All
Phase N/A
75 participants needed
1 Location

Brief description of study

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH). NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own. The study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-alcoholic Steatohepatitis,NASH
  • Age: 18 years - 99 years
  • Gender: All

Male or Female Age 18 or older Histological evidence of NASH

Updated on 04 Aug 2024. Study ID: 849168

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center